Value
5.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 5.0 |
SYRE · Why this verdict
Why Spyre Therapeutics (SYRE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.4/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
All company value is concentrated in four programs—SPY001, SPY002, SPY072, and SPY003—with no marketed product revenue, meaning any clinical setback in any single program meaningfully reduces total enterprise value. Bear case | At least 1 of the 4 programs advances to the next clinical stage milestone within 12 months, reducing the risk that the entire pipeline stalls simultaneously. | →Stable |
| CounterEarly-stage multi-program biotech companies routinely carry binary risk by design; diversified pipeline concentration is actually better than a single-asset company and is appropriate for the development stage. | ||
A golden cross with price above all moving averages, RSI at 63, rising on-balance volume, and an analyst rating of 8.64 out of 10 with significant consensus price upside indicate that the market and institutional analysts are constructive on the near-term outlook. V9 | Price remains above the 200-day moving average for at least 6 of the next 9 months and analyst consensus rating stays above 7.5. | →Stable |
| CounterAnalyst ratings on early-stage biotechs are structurally biased upward, particularly from coverage-initiating banks with investment banking relationships; sentiment scores are less informative than in established companies. | ||
The company is cash-burning with a negative free cash flow ratio, a Piotroski F-Score of only 2 out of 9, and a quality score of 1.2, all well below minimum thresholds, reflecting the pre-commercial stage of development where cash consumption is the primary operational activity. Quality breakdown | Cash runway extends to at least 18 months from the current date without requiring a dilutive equity raise, preserving value for existing shareholders. | →Stable |
| CounterPre-revenue biotechs by design have low quality scores; the Piotroski framework is not designed for pre-commercial companies and penalizes them regardless of pipeline quality. | ||
A 16% short interest and implied volatility near 99% reflect both directional skepticism and market uncertainty about the timing and outcome of upcoming clinical data events. Risk breakdown | Short interest falls below 12% within 6 months as at least one positive clinical data readout reduces uncertainty and reduces the short seller base. | →Stable |
| CounterHigh short interest in clinical-stage biotechs often coexists with strong momentum; if a data readout is positive, the short squeeze dynamic could amplify returns by more than 30%. | ||
All company value is concentrated in four programs—SPY001, SPY002, SPY072, and SPY003—with no marketed product revenue, meaning any clinical setback in any single program meaningfully reduces total enterprise value.
→StableBear case
- Expectation
- At least 1 of the 4 programs advances to the next clinical stage milestone within 12 months, reducing the risk that the entire pipeline stalls simultaneously.
CounterEarly-stage multi-program biotech companies routinely carry binary risk by design; diversified pipeline concentration is actually better than a single-asset company and is appropriate for the development stage.
A golden cross with price above all moving averages, RSI at 63, rising on-balance volume, and an analyst rating of 8.64 out of 10 with significant consensus price upside indicate that the market and institutional analysts are constructive on the near-term outlook.
→StableV9
- Expectation
- Price remains above the 200-day moving average for at least 6 of the next 9 months and analyst consensus rating stays above 7.5.
CounterAnalyst ratings on early-stage biotechs are structurally biased upward, particularly from coverage-initiating banks with investment banking relationships; sentiment scores are less informative than in established companies.
The company is cash-burning with a negative free cash flow ratio, a Piotroski F-Score of only 2 out of 9, and a quality score of 1.2, all well below minimum thresholds, reflecting the pre-commercial stage of development where cash consumption is the primary operational activity.
→StableQuality breakdown
- Expectation
- Cash runway extends to at least 18 months from the current date without requiring a dilutive equity raise, preserving value for existing shareholders.
CounterPre-revenue biotechs by design have low quality scores; the Piotroski framework is not designed for pre-commercial companies and penalizes them regardless of pipeline quality.
A 16% short interest and implied volatility near 99% reflect both directional skepticism and market uncertainty about the timing and outcome of upcoming clinical data events.
→StableRisk breakdown
- Expectation
- Short interest falls below 12% within 6 months as at least one positive clinical data readout reduces uncertainty and reduces the short seller base.
CounterHigh short interest in clinical-stage biotechs often coexists with strong momentum; if a data readout is positive, the short squeeze dynamic could amplify returns by more than 30%.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Spyre Therapeutics is a clinical-stage biotech with strong price momentum, a breakout technical setup, and strong analyst sentiment at 8.6 average rating, but the company burns cash with a negative Piotroski F-Score of only 2 and its entire value rests on four early-stage drug programs with no revenue base.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.8 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 1.6 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.6 |
| Price target | 6.9 |
| erm sentiment | 5.0 |
Insider
3.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Heavy insider selling — $418,695,449 (5.565% of mkt cap)
Peer rank
5.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.6 |
| growth rank | 5.0 |
Technical
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.8 |
| support resistance | 4.3 |
| 52w position | 7.4 |
Risk (lower is worse)
2.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.9 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 0.0 |
- ▸High short interest justified: 16%
- ▸High IV: 141%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (5)
- MOMENTUM:5.2>=4.5
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:0.1<1.5@spot
- INSIDER:5.57%=EXTREME
Warning (2)
- MOMENTUM:5.2<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.13
Upside
+1.9%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 59 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.1 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.1<1.5@spot.
The strongest dimensions are Sentiment at 7.1, Catalyst at 6.7, and Momentum at 5.2; the weakest are Quality at 1.2, Risk (lower is worse) at 2.0, and Insider at 3.0. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 0.13 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Pipeline Concentration Binary Risk
Trip ifAny of the 4 pipeline programs fails a primary endpoint in a clinical trial, resulting in a price drop below $70, more than 16% below the current price of $83.58.
- P2Breakout Momentum Analyst Sentiment
Trip ifPrice falls below the 200-day moving average and the golden cross reverts to a death cross, with price dropping more than 15% from the current level of $83.58.
- P3Cash Burn Quality Below Floor
Trip ifThe company announces a new equity raise at a price below $75, representing more than 10% dilution below the current price of $83.58, indicating cash runway is shorter than 12 months.
- P4High Short Interest Elevated Iv
Trip ifShort interest rises above 20% of float, indicating growing conviction among short sellers that is more than 4 percentage points above the current 16% level.